Patents Assigned to CHDI Foundation Inc.
  • Heterocyclic compounds and imaging agents for imaging huntingtin protein
    Patent number: 11918662
    Abstract: Provided herein are certain compounds and imaging agents useful for detecting a disease or condition associated with protein aggregation, compositions thereof, and methods of their use.
    Type: Grant
    Filed: June 10, 2021
    Date of Patent: March 5, 2024
    Assignee: CHDI Foundation, Inc.
    Inventors: Longbin Liu, Matthew Lee, Celia Dominguez, Peter David Johnson, Catherine Jane Greenaway, Kanika Khurana, Matthew Robert Mills, Filippo Rota
  • Probes for imaging Huntingtin protein
    Patent number: 11851446
    Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: December 26, 2023
    Assignee: CHDI Foundation, Inc.
    Inventors: Celia Dominguez, John Wityak, Jonathan Bard, Alex Kiselyov, Christopher John Brown, Michael Edward Prime, Peter David Johnson, Daniel Clark-Frew
  • HTT modulators for treating Huntington's disease
    Patent number: 11806346
    Abstract: Provided herein are certain compounds useful as HTT modulators. Such compound are useful in the treatment of Huntington's disease.
    Type: Grant
    Filed: May 12, 2021
    Date of Patent: November 7, 2023
    Assignee: CHDI Foundation, Inc.
    Inventors: Celia Dominguez, Elizabeth M. Doherty, Longbin Liu, Matthew Lee, Mark Stuart Chambers, Karine Fabienne Malagu, Perla Breccia, Alan F. Haughan, Huw D. Vater, Andrew J. Stott, William R. K. Esmieu, Stephen John Webster, Amanda J. Van De Poël
  • ATM kinase inhibitors and compositions and methods of use thereof
    Patent number: 11685734
    Abstract: Provided are certain ATM kinase inhibitors of Formula I: Also provided herein are compositions of such compounds, and methods of their use.
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: June 27, 2023
    Assignee: CHDI Foundation, Inc.
    Inventors: Leticia M. Toledo-Sherman, Celia Dominguez, Perla Breccia, Amanda J. Van De Poël, Grant Wishart, Huw D. Vater, William R. K. Esmieu, Cole Clissold, Wesley P. Blackaby
  • Zinc finger protein compositions for modulation of huntingtin (Htt)
    Patent number: 11421007
    Abstract: The present disclosure is in the field of modulation of Htt gene expression and HTT protein levels.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: August 23, 2022
    Assignees: Sangamo Therapeutics, Inc., CHDI Foundation, Inc.
    Inventors: Steven Froelich, Ignacio Munoz-Sanjuan, Edward J. Rebar, Bryan Zeitler, H. Steve Zhang
  • Compounds for targeting mutant huntingtin protein and uses thereof
    Patent number: 11389438
    Abstract: The present disclosure relates generally to compounds that simultaneously bind both mutant huntingtin protein (mHTT) and an ubiquitin E3 ligase and their use as therapeutic agents, for example, in treating diseases, such as neurodegenerative disorders caused by aggregation of mHTT.
    Type: Grant
    Filed: February 24, 2020
    Date of Patent: July 19, 2022
    Assignee: CHDI Foundation, Inc.
    Inventors: Celia Dominguez, Jonathan Bard, Matthew R. Lee, Longbin Liu, Michael Edward Prime, Samuel Coe
  • Probes for imaging huntingtin protein
    Patent number: 11344637
    Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: May 31, 2022
    Assignee: CHDI FOUNDATION, INC.
    Inventors: Celia Dominguez, John Wityak, Jonathan Bard, Christopher John Brown, Michael Edward Prime, Peter David Johnson, Thomas Martin Krulle, Daniel Clark-Frew, Duane Higgins, Matthew Robert Mills, Richard Waldron Marston, Samuel Coe, Samantha Brown, Sarah Hayes
  • Zinc finger protein compositions for modulation of huntingtin (Htt)
    Patent number: 11279739
    Abstract: The present disclosure is in the field of modulation of Htt gene expression and HTT protein levels.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: March 22, 2022
    Assignees: Sangamo Therapeutics, Inc., CHDI Foundation, Inc.
    Inventors: Steven Froelich, Ignacio Munoz-Sanjuan, Edward J. Rebar, Bryan Zeitler, H. Steve Zhang
  • Solid forms of a kynurenine-3-monooxygenase inhibitor
    Patent number: 11173156
    Abstract: Forms of 6-(3-chloro-4-cyclopropoxyphenyl)pyrimidine-4-carboxylic acid (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the forms of Compound I and salts or co-crystals thereof.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: November 16, 2021
    Assignee: CHDI Foundation, Inc.
    Inventors: Leticia M. Toledo-Sherman, Celia Dominguez, Vinod Khetarpal, Travis Lee Houston, Stephan D. Parent, Jian-xie Chen, Charles H. Montgomery, Geetha Banda
  • Methods and compositions for treating Huntington's Disease
    Patent number: 11110154
    Abstract: Disclosed herein are methods and compositions for treating or preventing Huntington's Disease.
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: September 7, 2021
    Assignees: Sangamo Therapeutics, Inc., CHDI Foundation, Inc.
    Inventors: Steven Froelich, Seung Kwak, Ignacio Munoz-Sanjuan, H. Steve Zhang
  • Probes for imaging huntingtin protein
    Patent number: 11104691
    Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: August 31, 2021
    Assignee: CHDI Foundation, Inc.
    Inventors: Celia Dominguez, John Wityak, Jonathan Bard, Alex Kiselyov, Christopher John Brown, Michael Edward Prime, Peter David Johnson, Daniel Clark-Frew
  • Probes for imaging huntingtin protein
    Patent number: 11071793
    Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: July 27, 2021
    Assignee: CHDI Foundation, Inc.
    Inventors: Celia Dominguez, John Wityak, Jonathan Bard, Christopher John Brown, Thomas Martin Krülle, Daniel Clark-Frew, Sarah Hayes
  • Probes for imaging huntingtin protein
    Patent number: 11059836
    Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: July 13, 2021
    Assignee: CHDI Foundation, Inc.
    Inventors: Celia Dominguez, Samuel Coe, Peter David Johnson, Michael Edward Prime, Christopher John Brown, Sébastien René Gabriel Galan, Paul Richard Giles, Jonathan Bard, Elise Luciennen Paulette Gadouleau, Thomas Martin Krülle, Daniel Clark-Frew, John Wityak, Alex Kiselyov, Sarah Hayes
  • Probes for imaging huntingtin protein
    Patent number: 10907197
    Abstract: Provided are imaging agents comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: February 2, 2021
    Assignee: CHDI Foundation, Inc.
    Inventors: Celia Dominguez, John Wityak, Jonathan Bard, Christopher John Brown, Michael Edward Prime, Derek Alexander Weddell, Daryl Simon Walter, Paul Richard Giles, Ian James Wigginton, Malcolm George Taylor, Sébastien René Gabriel Galan, Peter David Johnson, Thomas Martin Krülle, Inaki Morao, Daniel Clark-Frew
  • Probes for imaging huntingtin protein
    Patent number: 10765764
    Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: September 8, 2020
    Assignee: CHDI Foundation, Inc.
    Inventors: Celia Dominguez, John Wityak, Jonathan Bard, Christopher John Brown, Michael Edward Prime, Peter David Johnson, Thomas Martin Krulle, Daniel Clark-Frew, Duane Higgins, Matthew Robert Mills, Richard Waldron Marston, Samuel Coe, Samantha Brown, Sarah Hayes
  • Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
    Patent number: 10501433
    Abstract: Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: December 10, 2019
    Assignee: CHDI Foundation, Inc.
    Inventors: Celia Dominguez, Leticia Toledo-Sherman, Michael Prime, William Mitchell, Naomi Went
  • Probes for imaging huntingtin protein
    Patent number: 10479802
    Abstract: Provided are imaging agents comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: November 19, 2019
    Assignee: CHDI Foundation, Inc.
    Inventors: Celia Dominguez, Samuel Coe, Jonathan Bard, Peter David Johnson, Michael Edward Prime, Christopher John Brown, Sébastien René Gabriel Galan, Paul Richard Giles, Elise Luciennen Paulette Gadouleau, Thomas Martin Krülle, Daniel Clark-Frew, John Wityak, Alex Kiselyov, Sarah Hayes
  • Histone deacetylase inhibitors and compositions and methods of use thereof
    Patent number: 10457675
    Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: October 29, 2019
    Assignee: CHDI Foundation, Inc.
    Inventors: Celia Dominguez, Ignacio Muñoz-Sanjuán, Roland W. Bürli, Christopher A. Luckhurst, Daniel R. Allen, Gilles Raphy, Perla Breccia, Alan F. Haughan, Grant Wishart, Samantha J. Hughes, Rebecca E. Jarvis, Huw D. Vater, Stephen D. Penrose, Michael Wall, Andrew J. Stott, Elizabeth A. Saville-Stones
  • Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
    Patent number: 10442782
    Abstract: Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: October 15, 2019
    Assignee: CHDI Foundation, Inc.
    Inventors: Leticia M. Toledo-Sherman, Celia Dominguez, Michael Prime, William Leonard Mitchell, Peter Johnson, Naomi Went
  • Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
    Patent number: 10428054
    Abstract: Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: October 1, 2019
    Assignee: CHDI Foundation, Inc.
    Inventors: Leticia M. Toledo-Sherman, Celia Dominguez, Michael Prime, William Mitchell, Naomi Went